Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire

May 08

IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

Bank of America Securities 2026 Health Care Conference on Tuesday, May 12^th, at 3:40 p.m. PT / 6:40 p.m. ET.
H.C. Wainwright 4^th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19^th, at 8:00 a.m. PT / 11:00 a.m. ET.
Stifel 2026 Virtual Ophthalmology Forum on Tuesday, May 26^th, at 12:30 p.m. PT / 3:30 p.m. ET.

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2633177025"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633177025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633177025?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633177025","market":"us","top_or_hot":-1,"title":"Tarsus to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>IRVINE, Calif., May  07, 2026 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/TARS\">Tarsus Pharmaceuticals, Inc.</a> (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:</p> <ul type=\"disc\"><li>Bank of America Securities 2026 Health Care Conference on Tuesday, May 12<sup>th</sup>, at 3:40 p.m. PT / 6:40 p.m. ET.</li><li>H.C. Wainwright 4<sup>th</sup> Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19<sup>th</sup>, at 8:00 a.m. PT / 11:00 a.m. ET.</li><li><a href=\"https://laohu8.com/S/SFB\">Stifel</a> 2026 Virtual Ophthalmology Forum on Tuesday, May 26<sup>th</sup>, at 12:30 p.m. PT / 3:30 p.m. ET.<br/><br/></li></ul> <p>Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.</p> <p><strong>About Tarsus Pharmaceuticals, Inc.</strong><br/>Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY<sup>®</sup> (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of <em>Demodex</em> blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2.</p> <p><strong>Media Contact:</strong><br/>Adrienne Kemp<br/>Sr. Director, Corporate Communications<br/>(949) 922-0801<br/>AKemp@tarsusrx.com</p> <p><strong>Investor Contact:</strong><br/>David Nakasone<br/>Head of Investor Relations<br/>(949) 620-3223<br/>DNakasone@tarsusrx.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MzgyOTM3ZWYtNDVjNC00MmY2LWJhMWItZTgxNWIyZGIxYWRiLTEyMTU0MTctMjAyNi0wNS0wNy1lbg==/tiny/Tarsus-Pharmaceuticals-Inc.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tarsus to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTarsus to Participate in Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2026-05-08 05:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>IRVINE, Calif., May  07, 2026 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/TARS\">Tarsus Pharmaceuticals, Inc.</a> (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:</p> <ul type=\"disc\"><li>Bank of America Securities 2026 Health Care Conference on Tuesday, May 12<sup>th</sup>, at 3:40 p.m. PT / 6:40 p.m. ET.</li><li>H.C. Wainwright 4<sup>th</sup> Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19<sup>th</sup>, at 8:00 a.m. PT / 11:00 a.m. ET.</li><li><a href=\"https://laohu8.com/S/SFB\">Stifel</a> 2026 Virtual Ophthalmology Forum on Tuesday, May 26<sup>th</sup>, at 12:30 p.m. PT / 3:30 p.m. ET.<br/><br/></li></ul> <p>Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.</p> <p><strong>About Tarsus Pharmaceuticals, Inc.</strong><br/>Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY<sup>®</sup> (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of <em>Demodex</em> blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2.</p> <p><strong>Media Contact:</strong><br/>Adrienne Kemp<br/>Sr. Director, Corporate Communications<br/>(949) 922-0801<br/>AKemp@tarsusrx.com</p> <p><strong>Investor Contact:</strong><br/>David Nakasone<br/>Head of Investor Relations<br/>(949) 620-3223<br/>DNakasone@tarsusrx.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MzgyOTM3ZWYtNDVjNC00MmY2LWJhMWItZTgxNWIyZGIxYWRiLTEyMTU0MTctMjAyNi0wNS0wNy1lbg==/tiny/Tarsus-Pharmaceuticals-Inc.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290686/0/en/Tarsus-to-Participate-in-Upcoming-Investor-Conferences.html","article_id":"2633177025","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633177025","pubTimestamp":1778187600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"IRVINE, Calif., May  07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Bank","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TARS":"Tarsus Pharmaceuticals, Inc."},"translate_title":"塔尔苏斯将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARS":1},"content_text":"IRVINE, Calif., May  07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2026 Health Care Conference on Tuesday, May 12th, at 3:40 p.m. PT / 6:40 p.m. ET.H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19th, at 8:00 a.m. PT / 11:00 a.m. ET.Stifel 2026 Virtual Ophthalmology Forum on Tuesday, May 26th, at 12:30 p.m. PT / 3:30 p.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2. Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801AKemp@tarsusrx.com Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@tarsusrx.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}